Risks, Benefits of Long-Term Drug Therapy for Osteoporosis Reviewed
Position paper outlines research gaps for clinical management of long-term osteoporosis drug therapy
Osteoporosis
Evenity Approved to Treat Osteoporosis in Postmenopausal Women at High Risk for Fracture
The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.
Treatments for Preventing Fracture in Postmenopausal Women Compared
Overall, treatments that were associated with the greatest relative risk reduction in fragility fractures included teriparatide, abaloparatide, denosumab, romosozumab and most bisphosphonate.
Rates of Osteonecrosis of the Jaw Low for Denosumab-Treated Women
For denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events, including dental implants, tooth extraction, natural tooth loss, scaling/root planning, and jaw surgery, are common and associated with osteonecrosis of the jaw.
FDA Panel Votes on Novel Osteoporosis Treatment Evenity
In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.
Romosozumab Followed by Alendronate Superior in Reducing Fracture Risk
ARCH (Active-contRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk of Fracture) was a multicenter, international, randomized, double-blind, alendronate-controlled study (n=4,093) in postmenopausal women with osteoporosis at high risk for fracture based on previous fracture history.
Fracture Risk Reduced with Abaloparatide Followed by Alendronate
The data showed a statistically significant fracture risk reduction through 3.5 years.
Fulranumab for Osteoarthritis Pain
Sanga, Panna MD et al. “Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study”
New Position Paper on Screening for Osteoporosis Therapy Adherence Published
The International Osteoporosis Foundation and European Calcified Tissue Society Working Group proposed a screening strategy measuring certain bone turnover markers in patients who have initiated oral bisphosphonate therapy for postmenopausal osteoporosis as a practical way to identify low adherence.
Denosumab Prevents Osteoporosis in Autoimmune Liver Diseases
Denosumab injections prevent osteoporosis in patients with primary biliary cholangitis and autoimmune hepatitis, with few adverse effects.
